Ascletis reveals promising obesity drug data at ObesityWeek 2025

Ascletis Pharma Inc. presented full analyses of its phase Ib study of ASC30 oral tablet, phase Ib study of ASC30 injection, and preclinical study of a combination of ASC31 and ASC47 at ObesityWeek 2025. The ASC30 once-daily oral tablet demonstrated up to a 6.5% placebo-adjusted mean body weight reduction from baseline after 28 days, with the highest dose (60 mg) showing up to a 9.3% reduction. It was reported as safe and well-tolerated with mild-to-moderate gastrointestinal adverse events.

The phase Ib study data for ASC30 subcutaneous (SQ) injection revealed extended half-lives of 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B). These findings support once-monthly treatment and once-quarterly maintenance therapies, respectively. No serious adverse events or Grade ≥ 3 adverse events were observed, with GI-related events being mild to moderate.

In preclinical studies, the combination of ASC47 and ASC31, a novel peptide agonist, significantly outperformed both tirzepatide and ASC31 monotherapy in diet-induced obesity (DIO) mice, showing a 134% greater reduction in weight loss compared to ASC31 alone. These results, according to the company, validate its proprietary artificial intelligence-assisted structure-based drug discovery (AISBDD) and ultra-long-acting platform (ULAP) technologies.